Precision Business Insights (PBI) in its report titled “Global peptide API CMO Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024” assesses the market performance over seven years forecast period over 2018-2024. The global peptide API CMO market was valued at US$ XX Mn in 2018 and increasing at a significant CAGR over the forecast timeframe owing to surge in the scientific advancements and rising number of pharmaceutical and biopharmaceutical companies across the globe are expected to propel the growth of the market.
Global peptide API CMO market segmented on the basis of product type, therapeutic area, end user, and region.
For request sample: [URL]https://www.precisionbusinessinsights.com/request-sample?product_id=36185[/URL]
Peptide Generic API Dominates the Global peptide API CMO Market
Based on product type, global peptide API CMO market segmented into Peptide Generic API, peptide NCEs. Peptide Generic API dominated the global peptide API CMO market in 2018 and estimated to dominate over the forecast period owing to increase in prevalence of various types of cancers and other diseases, low risk in investing on these products, more profits if the product gets approved than innovation of newer protein and peptide drugs, rise in awareness about the peptide API CMO among various healthcare sectors, and patent filings by the market players are surge the market over the forecast years.
North America Leads the Global peptide API CMO Market
PBI’s global peptide API CMO market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis,
Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players
Key player’s profiles in the report are
• ScinoPharm Taiwan, Ltd. (Taiwan)
• Corden Pharma International (Germany)
• Bachem AG (Switzerland)
• Biopeptek Pharmaceuticals LLC. (U.S.)
• Hybio Pharmaceutical Co., Ltd. (China)
• Chinese Peptide Company (China)
• AmbioPharm, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• PolyPeptide Group (Sweden)
• Chemi S.p.A. (Italy).
Detailed Segmentation
By Product Type
o Peptide Generic API
o Peptide NCEs
By Therapeutic area
o Oncology
o Cardiovascular Disorders
o metabolic Disorders
o CNS Disorders
o Respiratory Disorders
o Gastrointestinal Disorders
o Anti-infective
o Dermatology
o Renal Disorders
o Others
End User
o Pharmaceutical Companies
o Biopharmaceutical Companies
Geography
o North America
• U.S
• Canada
o Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
o Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
o Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA
For more information:[URL] https://www.precisionbusinessinsights.com/market-reports/global-peptide-api-cmo-market[/URL]